CD19 and acute lymphoblastic leukemia: For example, although 70% to 90% of relapsed or refractory ALL patients exhibit long-term responses to CD19-targeting CAR-T cell therapy, recent follow-up data indicate a common resistance mechanism, with 30% to 70% of patients who relapse after treatment showing downregulation or loss of the CD19 antigen (76).